It was learned that Platinum Pharmaceuticals announced the successful completion of the US$85 million Series B financing. This round of financing was led by the Singapore government investment company GIC, the China Life Insurance Fund and Xiangfeng Investment, and the A-round investment institution Shangyi Capital and Junlian Capital. cast.
Dr. Wang Jinsong, founder, chairman and CEO of Platinum Pharmaceuticals, said that this round of financing will be used to accelerate the growth of the company's innovative product line, especially the company's clinical phase projects and pre-clinical projects.
At the beginning of 2018, and Platinum Pharmaceuticals announced the successful completion of the A+ round of financing from CDH Investment and Shangyu Capital.
In December 2016, Platinum Pharmaceuticals announced the completion of a $50 million Series A round of financing, and acquired the biological technology company Harbour Antibodies BV and its subsidiaries based in the Netherlands with a fully human-derived antibody-transgenic mouse technology platform.
According to public information, Founded in 2016, Platinum Pharmaceuticals is a global biopharmaceutical company that develops innovations for cancer and immune diseases using its globally patented two universal human antibody transgenic mouse platform (Harbour Mice). therapy. And Platinum Pharmaceuticals also rapidly expand its new drug research and development pipeline through diversified cooperation with business partners. At the same time, Platinum Pharmaceuticals, through its wholly-owned subsidiary, Harbour Antibodies BV, has licensed its patented technology platform to global biopharmaceutical companies and academic institutions for the development of new antibody-based drugs.
Since 2018, Platinum Pharmaceuticals has successfully submitted three new drug clinical trial applications for two products to Chinese drug regulatory agencies to develop innovative drugs for the urgently needed immune diseases of Chinese patients; and recently introduced the Chinese market for GBR 1302, the first bispecific antibody candidate for HER2-positive cancer including breast and gastric cancer, and A167, an antibody candidate for PD-L1, a key target for tumor immunity, is developed and produced in the global market outside the Chinese market. And the right to operate and the right to combine drugs.
Dr. Wang Jinsong is currently a Visiting Assistant Professor of the Department of Rheumatology and Immunology, Faculty of Medicine, University of Pennsylvania, Chairman of the Advisory Board of the Pharmaceutical Information Association (DIA), and a Standing Committee Member of the Cancer Accuracy Medical Committee of the China Anti-Cancer Association. Prior to founding and Platinum, Dr. Wang Jinsong worked for Sanofi as President of China R&D Center and Head of Translational Medicine in Asia Pacific. Prior to this, Dr. Wang held various important positions in the field of drug discovery and clinical pharmacology at Baimei Squibb. He has led and presided over a number of global pre-clinical development and clinical trial projects. Prior to this, Dr. Wang was the head of the Wyeth Pharmaceuticals Translational Medicine Department for Inflammation, Musculoskeletal and Women's Health.
Magnetostrictive System Scaler
A magnetostrictive system scaler is a dental instrument used for removing calculus and plaque from the teeth. It utilizes high-frequency vibrations generated by a magnetostrictive transducer to break down and remove the deposits from the tooth surface.
Magnetostrictive System Scaler,Cavitron Type Scaler,Dentsply Type Scaler,Dental Magneto Scaler
Rolence Enterprise Inc. , https://www.rolencedent.com